All hepatitis C virus genotypes respond to therapy
Mark L. Fuerst
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.
Females, Hispanics screened less often for highly curable infection.
More patients could take advantage of shorter direct-acting antiviral treatment duration.
With the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
More effort needed to integrate screening with follow-up care to prevent spread of the virus.
An innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
Timely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.